What is the actual cost of regorafenib after medical insurance reimbursement?

Regorafenib is a multi-target tyrosine kinase inhibitor that has been approved by the National Medical Products Administration for the treatment of advanced colorectal cancer, gastrointestinal stromal tumors (GIST) and hepatocellular carcinoma (HCC). The drug achieves anti-tumor effects by inhibiting the growth and spread of tumor cells and intervening in the tumor microenvironment. The mechanism of action of regorafenib is not limited to the tumor cells themselves, but also includes the inhibition of angiogenesis-related signaling pathways, so it has shown good clinical effects in the treatment of recurrent or refractory tumors.

With the continuous improvement of my country's anti-cancer drug policy, regorafenib has been included in the scope of medical insurance, allowing more patients to obtain cheaper treatment options. Especially for those patients with limited financial conditions, the reimbursement policy of medical insurance is undoubtedly important good news. The price for patients to purchase regorafenib directly in the country is usually around four to five thousand yuan. Compared with some innovative drugs, this price is already somewhat affordable, especially after reimbursement by medical insurance, the actual burden on patients is further reduced.

The specific medical insurance reimbursement amount will vary depending on the region and hospital where the patient is located. Therefore, it is recommended that patients consult the local hospital pharmacy in detail when seeking medical treatment to understand the corresponding reimbursement ratio and specific operating procedures. Generally speaking, medical insurance reimbursement can cover part of the drug cost, which helps reduce patients' financial pressure and allows them to focus more on the treatment itself rather than the cost of the drug.

During treatment with regorafenib, patients may experience some side effects, including but not limited to fatigue, hypertension, rash, oral mucositis, etc. Therefore, during the medication process, patients need to maintain close communication with their doctors and report discomfort symptoms in a timely manner so that necessary adjustments and treatments can be made. The doctor will develop an individualized treatment plan based on the patient's specific situation to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.stivarga-us.com/